Details of the Drug

General Information of Drug (ID: DMOSW35)

Drug Name

Felodipine

Synonyms

Agon; Felobeta; Felocor; Feloday; Felodipina; Felodipinum; Felodur; Felogamma; Felogard; Fensel; Flodil; Hydac; Lexxel; Logimax; Modip; Munobal; Penedil; Perfudal; Plandil; Plendil; Preslow; Prevex; Renedil; Splendil; AGON SR; AbZ Brand of Felodipine; Aliud Brand of Felodipine; Alphapharm Brand of Felodipine; Alpharma Brand of Felodipine; Astra Brand of Felodipine; AstraZeneca Brand of Felodipine; Aventis Brand of Felodipine; Azupharma Brand of Felodipine; BC Brand of Felodipine; Betapharm Brand of Felodipine; Ct Arzneimittel Brand of Felodipine; Felo Biochemie; Felo Puren; Felodipin AL; Felodipin AZU; Felodipin AbZ; Felodipin Heumann; Felodipin Stada; Felodipin dura; Felodipin ratiopharm; Felodipin von ct; FelodurER; Heumann Brand of Felodipine; Hexal Brand of Felodipine; Hoechst Brand of Felodipine; Merck dura Brand of Felodipine; Munobal Retard; Pharmaceutica Astra Brand of Felodipine; Pharmacia Spain Brandof Felodipine; Plendil Depottab; Plendil ER; Plendil Retard; Promed Brand of Felodipine; Ratiopharm Brand of Felodipine; Stadapharm Brand of Felodipine; TheraPharm Brand of Felodipine; Worwag Brand of Felodipine; F 9677; Felodipin 1A Pharma; H 154 82; H 15482; CGH-869; Ct-Arzneimittel Brand of Felodipine; Dl-Felodipine; Felo-Puren; Felodipin-ratiopharm; Felodipina [INN-Spanish]; Felodipinum [INN-Latin]; H 154-82; H 154/82; Heumann, Felodipin; Plendil (TN); AE-641/11429675; Felodipine [USAN:BAN:INN]; Felodipine [USAN:INN:BAN]; H-154/82; Felodipine (JAN/USP/INN); Plendil, Renedil, Feloday, Felodipine; Ethyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; (+/-)-ethylmethyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; 1A Brand of Felodipine; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-, ethyl methylester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-,ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester; 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate; 3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid ethyl methyl ester; 4-(2,3-dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester; 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester; 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antihypertensive Agents

Affected Organisms

Humans and other mammals

ATC Code

C08CA02: Felodipine

C08CA: Dihydropyridine derivatives

C08C: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS

C08: CALCIUM CHANNEL BLOCKERS

C: CARDIOVASCULAR SYSTEM

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

384.2

Logarithm of the Partition Coefficient (xlogp)

3.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Clearance: The drug present in the plasma can be removed from the body at the rate of 11 mL/min/kg [3]
Elimination: 0.25% of drug is excreted from urine in the unchanged form [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 17.5 - 31.5 hours [3]
Metabolism: The drug is metabolized via the hepatic []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.8666 micromolar/kg/day [4]
Unbound Fraction: The unbound fraction of drug in plasma is 0.0036% [3]
Vd: The volume of distribution (Vd) of drug is 10 L/kg []
Water Solubility: The ability of drug to dissolve in water is measured as 0.001 mg/mL [2]

Chemical Identifiers

Formula: C18H19Cl2NO4
IUPAC Name: 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
Canonical SMILES: CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C
InChI: InChI=1S/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3
InChIKey: RZTAMFZIAATZDJ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3333
ChEBI ID: CHEBI:585948
CAS Number: 72509-76-3
UNII: OL961R6O2C
DrugBank ID: DB01023
TTD ID: D0WN0U
VARIDT ID: DR00691
INTEDE ID: DR0685
ACDINA ID: D00267

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcium channel unspecific (CaC)	TT5HONZ	NOUNIPROTAC	Blocker	[5]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[6]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[7]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[8]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Gene/Protein Processing	[9]
Aryl hydrocarbon receptor (AHR)	OTFE4EYE	AHR_HUMAN	Gene/Protein Processing	[10]
Aurora kinase A (AURKA)	OTMX0HYT	AURKA_HUMAN	Protein Interaction/Cellular Processes	[11]
Bile acid receptor (NR1H4)	OTWZLPTB	NR1H4_HUMAN	Gene/Protein Processing	[9]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[12]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Gene/Protein Processing	[10]
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Gene/Protein Processing	[10]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Gene/Protein Processing	[13]
Cytochrome P450 2A6 (CYP2A6)	OT52TWG3	CP2A6_HUMAN	Gene/Protein Processing	[10]
Cytochrome P450 2B6 (CYP2B6)	OTOYO4S7	CP2B6_HUMAN	Gene/Protein Processing	[10]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Felodipine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Acebutolol	DM0TI4U	Moderate	Increased risk of cardiac depression by the combination of Felodipine and Acebutolol.	Hypertension [BA00-BA04]	[14]
Aliskiren	DM1BV7W	Moderate	Decreased clearance of Felodipine due to the transporter inhibition by Aliskiren.	Hypertension [BA00-BA04]	[15]
Penbutolol	DM4ES8F	Moderate	Increased risk of cardiac depression by the combination of Felodipine and Penbutolol.	Hypertension [BA00-BA04]	[14]
Nebivolol	DM7F1PA	Moderate	Increased risk of cardiac depression by the combination of Felodipine and Nebivolol.	Hypertension [BA00-BA04]	[14]
-----------

Coadministration of a Drug Treating the Disease Different from Felodipine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Felodipine caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[16]
Idarubicin	DMM0XGL	Moderate	Decreased clearance of Felodipine due to the transporter inhibition by Idarubicin.	Acute myeloid leukaemia [2A60]	[17]
Arn-509	DMT81LZ	Major	Increased metabolism of Felodipine caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[18]
Emapalumab	DMZG5WL	Moderate	Altered metabolism of Felodipine due to Emapalumab alters the formation of CYP450 enzymes.	Adaptive immunity immunodeficiency [4A01]	[19]
Siltuximab	DMGEATB	Moderate	Altered metabolism of Felodipine due to Siltuximab alters the formation of CYP450 enzymes.	Anemia [3A00-3A9Z]	[19]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Felodipine caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[20]
Aminophylline	DML2NIB	Minor	Altered absorption of Felodipine caused by Aminophylline.	Asthma [CA23]	[21]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Felodipine caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[22]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Felodipine caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[23]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Felodipine caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[23]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Felodipine and Cariprazine.	Bipolar disorder [6A60]	[24]
Erdafitinib	DMI782S	Moderate	Increased metabolism of Felodipine caused by Erdafitinib mediated induction of CYP450 enzyme.	Bladder cancer [2C94]	[25]
Talazoparib	DM1KS78	Moderate	Decreased clearance of Felodipine due to the transporter inhibition by Talazoparib.	Breast cancer [2C60-2C6Y]	[26]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Felodipine caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[27]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Felodipine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[28]
Oxtriphylline	DMLHSE3	Minor	Altered absorption of Felodipine caused by Oxtriphylline.	Cough [MD12]	[21]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Felodipine caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[18]
Ivacaftor	DMZC1HS	Moderate	Decreased clearance of Felodipine due to the transporter inhibition by Ivacaftor.	Cystic fibrosis [CA25]	[29]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Felodipine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[30]
Rivaroxaban	DMQMBZ1	Moderate	Decreased metabolism of Felodipine caused by Rivaroxaban mediated inhibition of CYP450 enzyme.	Deep vein thrombosis [BD71]	[31]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Felodipine and Selegiline.	Depression [6A70-6A7Z]	[32]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Felodipine and Isocarboxazid.	Depression [6A70-6A7Z]	[32]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Felodipine and OPC-34712.	Depression [6A70-6A7Z]	[24]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Felodipine caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[33]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Felodipine caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[34]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Felodipine caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[34]
Nadolol	DMW6GVL	Moderate	Increased risk of cardiac depression by the combination of Felodipine and Nadolol.	Essential hypertension [BA00]	[14]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Felodipine caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[35]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Felodipine caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[36]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Felodipine caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[20]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Felodipine caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[36]
Metipranolol	DMJMVKI	Moderate	Increased risk of cardiac depression by the combination of Felodipine and Metipranolol.	Glaucoma [9C61]	[37]
Levobetaxolol	DMSREPX	Moderate	Increased risk of cardiac depression by the combination of Felodipine and Levobetaxolol.	Glaucoma [9C61]	[37]
Levobunolol	DMTNFCQ	Moderate	Increased risk of cardiac depression by the combination of Felodipine and Levobunolol.	Glaucoma [9C61]	[37]
Carvedilol	DMHTEAO	Moderate	Increased risk of cardiac depression by the combination of Felodipine and Carvedilol.	Heart failure [BD10-BD1Z]	[14]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Felodipine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[38]
Simeprevir	DMLUA9D	Moderate	Decreased metabolism of Felodipine caused by Simeprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[39]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Felodipine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[38]
Rifampin	DMA8J1G	Major	Increased metabolism of Felodipine caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[18]
Rifapentine	DMCHV4I	Major	Increased metabolism of Felodipine caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[18]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Felodipine and Procarbazine.	Hodgkin lymphoma [2B30]	[32]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Felodipine caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Felodipine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[41]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Felodipine caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[42]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Felodipine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[43]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Felodipine caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[44]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Felodipine caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[45]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Felodipine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[46]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Felodipine caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[34]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Felodipine and ITI-007.	Insomnia [7A00-7A0Z]	[24]
Naloxegol	DML0B41	Minor	Decreased clearance of Felodipine due to the transporter inhibition by Naloxegol.	Large intestine motility disorder [DB32]	[47]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Felodipine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[48]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Felodipine caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[19]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Felodipine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[49]
GDC-0199	DMH0QKA	Major	Decreased clearance of Felodipine due to the transporter inhibition by GDC-0199.	Mature B-cell leukaemia [2A82]	[50]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Felodipine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[51]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Felodipine due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[50]
LGX818	DMNQXV8	Moderate	Increased metabolism of Felodipine caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[52]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Felodipine caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[53]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Felodipine and Thalidomide.	Multiple myeloma [2A83]	[50]
Siponimod	DM2R86O	Major	Increased risk of bradycardia by the combination of Felodipine and Siponimod.	Multiple sclerosis [8A40]	[50]
Fingolimod	DM5JVAN	Moderate	Increased risk of bradycardia by the combination of Felodipine and Fingolimod.	Multiple sclerosis [8A40]	[54]
Ozanimod	DMT6AM2	Moderate	Increased risk of atrioventricular block by the combination of Felodipine and Ozanimod.	Multiple sclerosis [8A40]	[55]
Romidepsin	DMT5GNL	Moderate	Decreased clearance of Felodipine due to the transporter inhibition by Romidepsin.	Mycosis fungoides [2B01]	[56]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Felodipine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[19]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Felodipine caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[57]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Felodipine and Promethazine.	Nausea/vomiting [MD90]	[24]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Felodipine caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[58]
S-297995	DM26IH8	Moderate	Decreased clearance of Felodipine due to the transporter inhibition by S-297995.	Opioid use disorder [6C43]	[19]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Felodipine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[59]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Felodipine and Safinamide.	Parkinsonism [8A00]	[32]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Felodipine and Rasagiline.	Parkinsonism [8A00]	[32]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Felodipine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[60]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Felodipine caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[61]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Felodipine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[62]
Enzalutamide	DMGL19D	Major	Increased metabolism of Felodipine caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[18]
Silodosin	DMJSBT6	Moderate	Decreased clearance of Felodipine due to the transporter inhibition by Silodosin.	Prostate hyperplasia [GA90]	[63]
Ustekinumab	DMHTYK3	Moderate	Altered metabolism of Felodipine due to Ustekinumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[19]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Felodipine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[24]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Felodipine and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[64]
Tocilizumab	DM7J6OR	Moderate	Altered metabolism of Felodipine due to Tocilizumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[19]
Canakinumab	DM8HLO5	Moderate	Altered metabolism of Felodipine due to Canakinumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[19]
Rilonacept	DMGLUQS	Moderate	Altered metabolism of Felodipine due to Rilonacept alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[19]
Golimumab	DMHZV7X	Moderate	Altered metabolism of Felodipine due to Golimumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[19]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Felodipine and Quetiapine.	Schizophrenia [6A20]	[24]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Felodipine and Aripiprazole.	Schizophrenia [6A20]	[24]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Felodipine and Iloperidone.	Schizophrenia [6A20]	[24]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Felodipine and Paliperidone.	Schizophrenia [6A20]	[24]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Felodipine and Molindone.	Schizophrenia [6A20]	[24]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Felodipine and Thiothixene.	Schizophrenia [6A20]	[24]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Felodipine and Amisulpride.	Schizophrenia [6A20]	[24]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Felodipine and Asenapine.	Schizophrenia [6A20]	[24]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Felodipine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[65]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Felodipine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[19]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Felodipine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[50]
Armodafinil	DMGB035	Moderate	Increased metabolism of Felodipine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[50]
LEE011	DMMX75K	Moderate	Decreased metabolism of Felodipine caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[66]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Felodipine caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[19]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Felodipine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[67]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Felodipine due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[59]
Apixaban	DM89JLN	Moderate	Decreased clearance of Felodipine due to the transporter inhibition by Apixaban.	Thrombosis [DB61-GB90]	[19]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Felodipine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[68]
-----------


⏷ Show the Full List of 102 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Butylated hydroxytoluene	E00336	31404	Antioxidant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Propyl gallate	E00075	4947	Antimicrobial preservative; Antioxidant
Quinoline yellow WS	E00309	24671	Colorant
Sodium stearyl fumarate	E00545	23665634	lubricant
Sunset yellow FCF	E00255	17730	Colorant
Aluminum silicate	E00587	56841952	Adsorbent; Diluent; Suspending agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butylhydroxyanisole	E00308	24667	Antimicrobial preservative; Antioxidant
Calcium silicate	E00533	21910000	Adsorbent; Anticaking agent; Diluent; Opacifying agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Hydrogenated polyoxyl 40 castor oil	E00662	Not Available	Emulsifying agent; Solubilizing agent; Surfactant
Hypromellose	E00634	Not Available	Coating agent
Kaolin	E00586	56841936	Adsorbent; Diluent; Suspending agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium aluminum silicate	E00462	3084116	Adsorbent; Binding agent; Disintegrant; Suspending agent; Viscosity-controlling agent
Magnesium oxide	E00232	14792	Anticaking agent; Diluent; Emulsifying agent; Glidant; Tonicity agent
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium aluminosilicate	E00349	19758701	Anticaking agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 30 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Felodipine 2.5 mg tablet	2.5 mg	24 HR Extended Release Oral Tablet	Oral
Felodipine 10 mg tablet	10 mg	24 HR Extended Release Tablet	Oral
Felodipine 10 mg tablet	10 mg	24 HR Extended Release Oral Tablet	Oral
Felodipine 5 mg tablet	5 mg	24 HR Extended Release Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4190).
2	BDDCS applied to over 900 drugs
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5	Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7.
6	The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers. J Clin Pharm Ther. 2017 Jun;42(3):345-349.
7	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
8	Drug Interactions Flockhart Table
9	Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
10	Optical isomers of dihydropyridine calcium channel blockers display enantiospecific effects on the expression and enzyme activities of human xenobiotics-metabolizing cytochromes P450. Toxicol Lett. 2016 Nov 16;262:173-186.
11	A Dual Non-ATP Analogue Inhibitor of Aurora Kinases A and B, Derived from Resorcinol with a Mixed Mode of Inhibition. Chem Biol Drug Des. 2016 Jun;87(6):958-67. doi: 10.1111/cbdd.12728. Epub 2016 Mar 21.
12	Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
13	Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
14	Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
15	Canadian Pharmacists Association.
16	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
17	Multum Information Services, Inc. Expert Review Panel.
18	Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
19	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
20	Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
21	Bratel T, Billing B, Dahlqvist R "Felodipine reduces the absorption of theophylline in man." Eur J Clin Pharmacol 36 (1989): 481-5. [PMID: 2753066]
22	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
23	Bailey DG, Bend JR, Arnold JMO, Tran LT, Spence JD "Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice." Clin Pharmacol Ther 60 (1996): 25-33. [PMID: 8689808]
24	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
25	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
26	Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
27	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
28	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
29	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
30	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
31	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
32	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
33	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
34	Bahls FH, Ozuna J, Ritchie DE "Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin." Neurology 41 (1991): 740-2. [PMID: 2027492]
35	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
36	Jalava KM, Olkkola KT, Neuvonen PJ "Itraconazole greatly increases plasma concentrations and effects of felodipine." Clin Pharmacol Ther 61 (1997): 410-5. [PMID: 9129558]
37	Henry M, Kay MM, Viccellio P "Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride." Am J Emerg Med 3 (1985): 334-6. [PMID: 2860911]
38	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
39	Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
40	Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
41	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
42	Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
43	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
44	Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
45	Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
46	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
47	Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
48	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
49	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
50	Cerner Multum, Inc. "Australian Product Information.".
51	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
52	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
53	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
54	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
55	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
56	Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
57	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
58	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
59	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
60	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
61	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
62	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
63	Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
64	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
65	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
66	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
67	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
68	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.